Behind-The-Counter Guidance Stalled, But Interest Grows To Expand Access

FDA executives say behind-the-counter status for nonprescription drugs resonates in discussions at the agency, but a former deputy commissioner says the agency's BTC interests are stifled by not having explicit authority